$ICDIQ
Independence Contract Drilling, Inc.

2023 Q3 Form 10-Q Financial Statement

#000153702823000030 Filed on August 03, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2
Revenue $44.16M $56.36M
YoY Change -10.14% 33.19%
Cost Of Revenue $27.49M $33.83M
YoY Change -12.39% 17.03%
Gross Profit $16.67M $22.53M
YoY Change -6.18% 68.01%
Gross Profit Margin 37.75% 39.98%
Selling, General & Admin $6.865M $5.224M
YoY Change -2.03% 7.49%
% of Gross Profit 41.18% 23.19%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $10.23M $11.41M
YoY Change 1.09% 15.81%
% of Gross Profit 61.37% 50.62%
Operating Expenses $6.865M $16.63M
YoY Change -2.03% 242.16%
Operating Profit $780.0K $5.900M
YoY Change 275.0% -922.87%
Interest Expense -$9.222M -$8.251M
YoY Change 13.88% 0.23%
% of Operating Profit -1182.31% -139.85%
Other Income/Expense, Net
YoY Change
Pretax Income -$8.442M -$4.358M
YoY Change 7.0% 636.15%
Income Tax -$844.0K -$197.0K
% Of Pretax Income
Net Earnings -$7.598M -$4.161M
YoY Change 5.62% 49.09%
Net Earnings / Revenue -17.2% -7.38%
Basic Earnings Per Share -$0.54 -$0.30
Diluted Earnings Per Share -$0.54 -$0.30
COMMON SHARES
Basic Shares Outstanding 14.08M 14.06M
Diluted Shares Outstanding 14.07M 14.05M

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $6.000M $5.584M
YoY Change -20.7% -23.44%
Cash & Equivalents $6.044M $5.584M
Short-Term Investments
Other Short-Term Assets $1.900M $2.732M
YoY Change 1762.75% 3448.05%
Inventory $1.900M $1.663M
Prepaid Expenses
Receivables $26.87M $34.51M
Other Receivables $0.00 $0.00
Total Short-Term Assets $36.65M $44.49M
YoY Change -20.17% 17.39%
LONG-TERM ASSETS
Property, Plant & Equipment $368.7M $374.9M
YoY Change 0.97% 4.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.199M $832.0K
YoY Change 48.17% -60.66%
Total Long-Term Assets $369.5M $375.7M
YoY Change 0.58% 4.77%
TOTAL ASSETS
Total Short-Term Assets $36.65M $44.49M
Total Long-Term Assets $369.5M $375.7M
Total Assets $406.1M $420.2M
YoY Change -1.72% 5.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $17.28M $18.30M
YoY Change -40.14% 7.24%
Accrued Expenses $12.13M $7.137M
YoY Change -7.86% -21.09%
Deferred Revenue $434.0K $1.089M
YoY Change -64.63% 335.6%
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $1.400M $1.947M
YoY Change -57.6% -39.63%
Total Short-Term Liabilities $30.81M $32.06M
YoY Change -32.21% -11.61%
LONG-TERM LIABILITIES
Long-Term Debt $156.3M $155.2M
YoY Change 14.29% 27.14%
Other Long-Term Liabilities $1.642M $8.276M
YoY Change -1.14% 318.61%
Total Long-Term Liabilities $1.642M $163.5M
YoY Change -1.14% 8170.66%
TOTAL LIABILITIES
Total Short-Term Liabilities $30.81M $32.06M
Total Long-Term Liabilities $1.642M $163.5M
Total Liabilities $199.7M $207.5M
YoY Change -1.77% 14.9%
SHAREHOLDERS EQUITY
Retained Earnings -$410.8M -$403.2M
YoY Change 2.06% 1.99%
Common Stock $621.2M $619.9M
YoY Change 0.78% 0.76%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $206.5M $212.8M
YoY Change
Total Liabilities & Shareholders Equity $406.1M $420.2M
YoY Change -1.72% 5.97%

Cashflow Statement

Concept 2023 Q3 2023 Q2
OPERATING ACTIVITIES
Net Income -$7.598M -$4.161M
YoY Change 5.62% 49.09%
Depreciation, Depletion And Amortization $10.23M $11.41M
YoY Change 1.09% 15.81%
Cash From Operating Activities $18.50M $21.50M
YoY Change 57.66% 421.24%
INVESTING ACTIVITIES
Capital Expenditures $5.480M $12.33M
YoY Change -153.93% -310.9%
Acquisitions
YoY Change
Other Investing Activities $1.590M $798.0K
YoY Change 107.3% -42.71%
Cash From Investing Activities -$3.880M -$11.53M
YoY Change -58.7% 158.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -14.15M -11.10M
YoY Change 584.24% 545.49%
NET CHANGE
Cash From Operating Activities 18.50M 21.50M
Cash From Investing Activities -3.880M -11.53M
Cash From Financing Activities -14.15M -11.10M
Net Change In Cash 470.0K -1.131M
YoY Change 72.79% -44.78%
FREE CASH FLOW
Cash From Operating Activities $18.50M $21.50M
Capital Expenditures $5.480M $12.33M
Free Cash Flow $13.02M $9.167M
YoY Change -40.53% -8.05%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2022Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2022Q4 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent
CY2022Q4 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
dei Entity Central Index Key
EntityCentralIndexKey
0001537028
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2023Q2 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P6M
CY2023Q2 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q2 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent
CY2023Q2 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Statement Of Financial Position Extensible List
FinanceLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
CY2023Q2 us-gaap Finance Lease Liability Current Statement Of Financial Position Extensible List
FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationsCurrent
CY2023Q2 us-gaap Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List
FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligations
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36590
dei Entity Registrant Name
EntityRegistrantName
Independence Contract Drilling, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
37-1653648
dei Entity Address Address Line1
EntityAddressAddressLine1
20475 State Highway 249
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 300
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77070
dei City Area Code
CityAreaCode
281
dei Local Phone Number
LocalPhoneNumber
598-1230
dei Security12b Title
Security12bTitle
Common Stock, $0.01 par value per share
dei Trading Symbol
TradingSymbol
ICD
dei Security Exchange Name
SecurityExchangeName
NYSE
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14084850
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5584000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5326000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34510000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
39775000
CY2023Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1663000
CY2022Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
1508000
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
325000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2732000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4736000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
44489000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
51670000
CY2023Q2 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
372226000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
376084000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3521000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1960000
CY2023Q2 us-gaap Assets
Assets
420236000
CY2022Q4 us-gaap Assets
Assets
429714000
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
1947000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
2485000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
18301000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
31946000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11813000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17608000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
32061000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
52039000
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
155235000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
143223000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
11895000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
12266000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
8276000
us-gaap Costs And Expenses
CostsAndExpenses
84658000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
3893000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-717000
us-gaap Operating Income Loss
OperatingIncomeLoss
12622000
us-gaap Operating Income Loss
OperatingIncomeLoss
-7354000
CY2023Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8251000
CY2022Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-8232000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-16970000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-12907000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7474000
CY2023Q2 us-gaap Liabilities
Liabilities
207467000
CY2022Q4 us-gaap Liabilities
Liabilities
215002000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14150819
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
13698851
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14065727
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
13613759
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
141000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
136000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
619807000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
617606000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-403246000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-399097000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
85092
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
85092
CY2023Q2 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3933000
CY2022Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
3933000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212769000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
214712000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
420236000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
429714000
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56356000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42313000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120112000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
77304000
CY2023Q2 us-gaap Direct Operating Costs
DirectOperatingCosts
33827000
CY2022Q2 us-gaap Direct Operating Costs
DirectOperatingCosts
28904000
us-gaap Direct Operating Costs
DirectOperatingCosts
71287000
us-gaap Direct Operating Costs
DirectOperatingCosts
56069000
CY2023Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5224000
CY2022Q2 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4860000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11951000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
10088000
CY2023Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
11405000
CY2022Q2 us-gaap Depreciation And Amortization
DepreciationAndAmortization
9848000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
22259000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
19599000
CY2023Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-2007000
CY2022Q2 us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
582000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1993000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1098000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
52463000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
43030000
us-gaap Costs And Expenses
CostsAndExpenses
107490000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-46347000
CY2022Q2 icd Change In Fair Value Of Embedded Derivative Liability
ChangeInFairValueOfEmbeddedDerivativeLiability
2408000
icd Change In Fair Value Of Embedded Derivative Liability
ChangeInFairValueOfEmbeddedDerivativeLiability
4265000
CY2022Q2 icd Realized Gain On Extinguishment Of Derivative
RealizedGainOnExtinguishmentOfDerivative
10765000
icd Realized Gain On Extinguishment Of Derivative
RealizedGainOnExtinguishmentOfDerivative
10765000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4358000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-592000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4348000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-60108000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-197000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2199000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-199000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1479000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4161000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2791000
us-gaap Net Income Loss
NetIncomeLoss
-4149000
us-gaap Net Income Loss
NetIncomeLoss
-61587000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.95
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14050000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14050000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13590000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13590000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13951000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13951000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12453000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12453000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
214712000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-385000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-34000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1374000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
12000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
215679000
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-4000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1255000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4161000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
212769000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
195229000
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation
StockGrantedDuringPeriodValueSharebasedCompensation
-32000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3360000
CY2022Q1 icd Stock Issued During Period Value Restructuring
StockIssuedDuringPeriodValueRestructuring
9163000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
292000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-58796000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
149216000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
-205000
CY2022Q2 icd Adjustments To Additional Paid In Capital Extinguishment Of Derivative
AdjustmentsToAdditionalPaidInCapitalExtinguishmentOfDerivative
69232000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
528000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2791000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
215980000
us-gaap Profit Loss
ProfitLoss
-4149000
us-gaap Profit Loss
ProfitLoss
-61587000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
22259000
us-gaap Depreciation Amortization And Accretion Net
DepreciationAmortizationAndAccretionNet
19599000
us-gaap Share Based Compensation
ShareBasedCompensation
2852000
us-gaap Share Based Compensation
ShareBasedCompensation
1203000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-1993000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
1098000
us-gaap Paid In Kind Interest
PaidInKindInterest
11619000
us-gaap Paid In Kind Interest
PaidInKindInterest
3193000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-46347000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
55000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
285000
icd Amortization Of Convertible Notes Issuance Costs And Debt Discount
AmortizationOfConvertibleNotesIssuanceCostsAndDebtDiscount
3546000
icd Amortization Of Convertible Notes Issuance Costs And Debt Discount
AmortizationOfConvertibleNotesIssuanceCostsAndDebtDiscount
2350000
icd Change In Fair Value Of Embedded Derivative Liability
ChangeInFairValueOfEmbeddedDerivativeLiability
4265000
icd Realized Gain On Extinguishment Of Derivative
RealizedGainOnExtinguishmentOfDerivative
10765000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-371000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1479000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-5265000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
4609000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
208000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
206000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-157000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2516000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-7964000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-509000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
35054000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
2463000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
31164000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
12125000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1546000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
1982000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-29618000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10143000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
157500000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
5000000
icd Repayments Of Term Loan Facility
RepaymentsOfTermLoanFacility
139076000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
17249000
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
1526000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
15560000
us-gaap Repayments Of Long Term Lines Of Credit
RepaymentsOfLongTermLinesOfCredit
2000
icd Payments Of Merger Consideration
PaymentsOfMergerConsideration
2902000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
-34000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
3155000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
389000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
32000
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
7057000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1444000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2278000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-5178000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10834000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
258000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3154000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5326000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4140000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5584000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7294000
us-gaap Interest Paid Net
InterestPaidNet
1138000
us-gaap Interest Paid Net
InterestPaidNet
4493000
us-gaap Income Taxes Paid
IncomeTaxesPaid
639000
icd Purchases Of Property Plant And Equipment In Accounts Payable
PurchasesOfPropertyPlantAndEquipmentInAccountsPayable
-11092000
icd Purchases Of Property Plant And Equipment In Accounts Payable
PurchasesOfPropertyPlantAndEquipmentInAccountsPayable
1130000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1359000
us-gaap Capital Lease Obligations Incurred
CapitalLeaseObligationsIncurred
1367000
icd Finance Lease Extinguishment Of Lease Obligations From Sale Of Assets
FinanceLeaseExtinguishmentOfLeaseObligationsFromSaleOfAssets
100000
icd Finance Lease Extinguishment Of Lease Obligations From Sale Of Assets
FinanceLeaseExtinguishmentOfLeaseObligationsFromSaleOfAssets
77000
icd Initial Embedded Derivative Liability Upon Issuance Of Convertible Notes
InitialEmbeddedDerivativeLiabilityUponIssuanceOfConvertibleNotes
75733000
icd Non Cash Or Part Non Cash Expenses Restructuring Fees
NonCashOrPartNonCashExpensesRestructuringFees
9163000
CY2022Q1 icd Market Price Of Oil
MarketPriceOfOil
123.64
CY2023Q3 icd Market Price Of Oil
MarketPriceOfOil
78.81
CY2022Q3 icd Natural Gas Price
NaturalGasPrice
9.85
CY2022Q4 icd Natural Gas Price
NaturalGasPrice
3.52
CY2023Q3 icd Natural Gas Price
NaturalGasPrice
2.68
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
0
CY2023Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56356000
CY2022Q2 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
42313000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
120112000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
77304000
CY2023Q2 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
0
CY2023Q2 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
34292000
CY2022Q4 us-gaap Contract With Customer Receivable After Allowance For Credit Loss
ContractWithCustomerReceivableAfterAllowanceForCreditLoss
39732000
CY2023Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1089000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
1158000
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
374000
CY2022Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
1544000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
915000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
540000
CY2023Q2 icd Contract With Customer Liability Increase Decrease From Cash Receipts
ContractWithCustomerLiabilityIncreaseDecreaseFromCashReceipts
95000
CY2022Q2 icd Contract With Customer Liability Increase Decrease From Cash Receipts
ContractWithCustomerLiabilityIncreaseDecreaseFromCashReceipts
93000
icd Contract With Customer Liability Increase Decrease From Cash Receipts
ContractWithCustomerLiabilityIncreaseDecreaseFromCashReceipts
846000
icd Contract With Customer Liability Increase Decrease From Cash Receipts
ContractWithCustomerLiabilityIncreaseDecreaseFromCashReceipts
248000
CY2023Q2 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
1089000
CY2023Q2 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
700000
CY2022Q4 us-gaap Capitalized Contract Cost Net Current
CapitalizedContractCostNetCurrent
300000
CY2023Q2 icd Capitalized Contract Cost Increase
CapitalizedContractCostIncrease
700000
icd Capitalized Contract Cost Increase
CapitalizedContractCostIncrease
1600000
CY2023Q2 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
700000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1200000
CY2022Q2 icd Capitalized Contract Cost Increase
CapitalizedContractCostIncrease
100000
icd Capitalized Contract Cost Increase
CapitalizedContractCostIncrease
2100000
CY2022Q2 us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
1400000
us-gaap Capitalized Contract Cost Amortization
CapitalizedContractCostAmortization
2600000
CY2023Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
298000
CY2022Q2 us-gaap Operating Lease Expense
OperatingLeaseExpense
193000
us-gaap Operating Lease Expense
OperatingLeaseExpense
489000
us-gaap Operating Lease Expense
OperatingLeaseExpense
387000
CY2023Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1933000
CY2022Q2 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1268000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
3662000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
2665000
CY2023Q2 us-gaap Variable Lease Cost
VariableLeaseCost
149000
CY2022Q2 us-gaap Variable Lease Cost
VariableLeaseCost
133000
us-gaap Variable Lease Cost
VariableLeaseCost
311000
us-gaap Variable Lease Cost
VariableLeaseCost
256000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
651000
CY2022Q2 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
330000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
1206000
us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
645000
CY2023Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
75000
CY2022Q2 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
99000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
148000
us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
213000
CY2023Q2 icd Finance Lease Cost
FinanceLeaseCost
726000
CY2022Q2 icd Finance Lease Cost
FinanceLeaseCost
429000
icd Finance Lease Cost
FinanceLeaseCost
1354000
icd Finance Lease Cost
FinanceLeaseCost
858000
CY2023Q2 us-gaap Lease Cost
LeaseCost
3106000
CY2022Q2 us-gaap Lease Cost
LeaseCost
2023000
us-gaap Lease Cost
LeaseCost
5816000
us-gaap Lease Cost
LeaseCost
4166000
us-gaap Operating Lease Payments
OperatingLeasePayments
432000
us-gaap Operating Lease Payments
OperatingLeasePayments
364000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
148000
us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
211000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1444000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
2278000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2106000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
153000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1359000
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
1367000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2689000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
976000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
985000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
751000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1813000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
373000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2798000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1124000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
8386000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
7307000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
3082000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
1994000
CY2023Q2 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
5304000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
5313000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1947000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2485000
CY2023Q2 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1757000
CY2022Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
1599000
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
3704000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
4084000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y8M12D
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2023Q2 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y9M18D
CY2022Q4 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M6D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0892
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.1086
CY2023Q2 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0813
CY2022Q4 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.0812
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
602000
CY2023Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
1343000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1086000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
1440000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
516000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
918000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
401000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
338000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
370000
CY2023Q2 us-gaap Finance Lease Liability Payments Due Year Four
FinanceLeaseLiabilityPaymentsDueYearFour
0
CY2023Q2 icd Lessee Operating Lease Liability To Be Paid After Year Four
LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
285000
CY2023Q2 icd Finance Lease Liability To Be Paid After Year Four
FinanceLeaseLiabilityToBePaidAfterYearFour
0
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3260000
CY2023Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
4039000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
462000
CY2023Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
335000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
2798000
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
3704000
CY2022Q1 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
1900000
CY2022Q2 us-gaap Embedded Derivative Gain Loss On Embedded Derivative Net
EmbeddedDerivativeGainLossOnEmbeddedDerivativeNet
2400000
CY2022Q2 us-gaap Embedded Derivative No Longer Bifurcated Amount Reclassified To Stockholders Equity
EmbeddedDerivativeNoLongerBifurcatedAmountReclassifiedToStockholdersEquity
69200000
CY2022Q2 icd Realized Gain On Extinguishment Of Derivative
RealizedGainOnExtinguishmentOfDerivative
10800000
CY2022Q2 us-gaap Debt Instrument Term
DebtInstrumentTerm
P3Y8M12D
CY2023Q1 icd Fair Value Assets Level Transfers Amount
FairValueAssetsLevelTransfersAmount
0
CY2023Q2 icd Fair Value Assets Level Transfers Amount
FairValueAssetsLevelTransfersAmount
0
CY2023Q2 us-gaap Prepaid Insurance
PrepaidInsurance
1053000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
3796000
CY2023Q2 us-gaap Deferred Costs Current
DeferredCostsCurrent
664000
CY2022Q4 us-gaap Deferred Costs Current
DeferredCostsCurrent
283000
CY2023Q2 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
1015000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
657000
CY2023Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2732000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4736000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4063000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6908000
CY2023Q2 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
918000
CY2022Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
3002000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1089000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1003000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
1996000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
3621000
CY2023Q2 us-gaap Interest Payable Current
InterestPayableCurrent
93000
CY2022Q4 us-gaap Interest Payable Current
InterestPayableCurrent
101000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
985000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
751000
CY2023Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2669000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2222000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11813000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17608000
CY2023Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
3704000
CY2022Q4 us-gaap Finance Lease Liability
FinanceLeaseLiability
4084000
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
193989000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Including Current Maturities
LongTermDebtAndCapitalLeaseObligationsIncludingCurrentMaturities
186061000
CY2023Q2 icd Convertible Notes Issuance Costs And Debt Discount
ConvertibleNotesIssuanceCostsAndDebtDiscount
36807000
CY2022Q4 icd Convertible Notes Issuance Costs And Debt Discount
ConvertibleNotesIssuanceCostsAndDebtDiscount
40353000
CY2023Q2 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
1947000
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
2485000
CY2023Q2 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
155235000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
143223000
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
5000000.0
us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
5000000.0
us-gaap Net Income Loss
NetIncomeLoss
-61587000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.21
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.21
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.30
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.30
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.95
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.95
icd Repayment Of Accrued Interest On Notes
RepaymentOfAccruedInterestOnNotes
200000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
472000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2852000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1203000
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
33332
icd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Remaining Term To Maturity
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRemainingTermToMaturity
P4Y7M6D
CY2022 icd Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Remaining Term To Maturity
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRemainingTermToMaturity
P5Y1M6D
CY2023Q2 us-gaap Shares Outstanding
SharesOutstanding
14065727
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
85092
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-4161000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-2791000
us-gaap Net Income Loss
NetIncomeLoss
-4149000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
14050000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13590000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
13951000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12453000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
14050000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13590000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
13951000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12453000
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40323000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
37877000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
39066000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23214000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.045
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.046
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-3.715
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.025
CY2023Q2 us-gaap Purchase Obligation
PurchaseObligation
1600000
CY2022Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
78900000
CY2022Q1 icd Investor S Rights Agreement Number Of Directors Who Can Be Nominated
InvestorSRightsAgreementNumberOfDirectorsWhoCanBeNominated
1
CY2022Q1 icd Investors Rights Agreement Principal Amount
InvestorsRightsAgreementPrincipalAmount
25000000.0
CY2022Q1 icd Investor S Rights Agreement Number Of Directors Who Can Be Nominated
InvestorSRightsAgreementNumberOfDirectorsWhoCanBeNominated
1
CY2022Q1 icd Number Of Holder Representatives That Have Right To Nominate Additional Representative As Director
NumberOfHolderRepresentativesThatHaveRightToNominateAdditionalRepresentativeAsDirector
2
CY2022Q1 icd Number Of Additional Representative To Be Appointed As Individual Director
NumberOfAdditionalRepresentativeToBeAppointedAsIndividualDirector
1
CY2022Q1 icd Number Of Holder Representatives That Have Right To Nominate Additional Representative As Director
NumberOfHolderRepresentativesThatHaveRightToNominateAdditionalRepresentativeAsDirector
2
CY2022Q1 icd Number Of Directors
NumberOfDirectors
6
CY2022Q3 icd Number Of Directors
NumberOfDirectors
7

Files In Submission

Name View Source Status
0001537028-23-000030-index-headers.html Edgar Link pending
0001537028-23-000030-index.html Edgar Link pending
0001537028-23-000030.txt Edgar Link pending
0001537028-23-000030-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
icd-20230630.xsd Edgar Link pending
icd-20230630x10q.htm Edgar Link pending
icd-20230630xex31d1.htm Edgar Link pending
icd-20230630xex31d2.htm Edgar Link pending
icd-20230630xex32d1.htm Edgar Link pending
icd-20230630xex32d2.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
icd-20230630_def.xml Edgar Link unprocessable
icd-20230630_lab.xml Edgar Link unprocessable
icd-20230630_pre.xml Edgar Link unprocessable
icd-20230630x10q_htm.xml Edgar Link completed
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
icd-20230630_cal.xml Edgar Link unprocessable